Open-label pilot study of ethosuximide as adjunctive therapy for relieving abdominal pain related to Irritable Bowel Syndrome.
Abdominal Pain
Ca++ channels
Ethosuximide
IBS
Journal
Journal of clinical pharmacy and therapeutics
ISSN: 1365-2710
Titre abrégé: J Clin Pharm Ther
Pays: England
ID NLM: 8704308
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
revised:
08
10
2021
received:
16
08
2021
accepted:
17
10
2021
pubmed:
3
11
2021
medline:
18
3
2022
entrez:
2
11
2021
Statut:
ppublish
Résumé
There is clear evidence for an association between irritable bowel syndrome (IBS) and visceral hypersensitivity. This clinical study aimed to assess the adjunct role of ethosuximide, an antiepileptic drug with T-type calcium channel blocking activity, in the relieving of IBS-related abdominal pain. This is a prospective, 3-month, randomized and controlled study of parallel groups. Fifty outpatients who met the inclusion criteria participated in the trial. Patients were allocated randomly: 25 received mebeverine 135 mg three times daily (t.i.d), whereas the other 25 received mebeverine 135 mg t.i.d and ethosuximide 500 mg t.i.d. At baseline and 12 weeks after starting the drug, patients were evaluated by a gastroenterologist. Serum tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-8 (IL-8), faecal myeloperoxidase and faecal neutrophile gelatinase-associated lipocalin (NGAL) levels were tested before and after treatment. The Numeric Pain Rating Scale (NRS) was assessed before and after three months of therapy. After 12 weeks, the ethosuximide group showed a statistically and significantly greater reduction in the serum levels of TNF-α, IL-6, IL-8, faecal myeloperoxidase and faecal NGAL in comparison with the control group after the treatment. Moreover, the ethosuximide group showed a statistically significant decrease in NRS compared with the mebeverine group. Ethosuximide could be a promising adjunct to antispasmodics in the treatment of IBS patients. Trial registration identifier: NCT04217733.
Substances chimiques
Ethosuximide
5SEH9X1D1D
Banques de données
ClinicalTrials.gov
['NCT04217733']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
306-312Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Picard E, Carvalho, FA, Agosti, F, et al. Inhibition of Cav3. 2 calcium channels: A new target for colonic hypersensitivity associated with low-grade inflammation. Br J Pharmacol. 2019;176(7):950-963.
Park JM, Choi MG, Kim YS. Quality of life of patients with irritable bowel syndrome in Korea. Qual Life Res. 2009;18(4):435-446.
Ng QX, Soh, AYS, Loke, W, Lim, DY, Yeo, WS. The role of inflammation in irritable bowel syndrome. (IBS). J Inflamm Res 2018;11:345.
Piche T, Barbara G, Aubert P, et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut. 2009;58(2):196-201.
Marger F, Gelot A, Alloui A, et al. T-type calcium channels contribute to colonic hypersensitivity in a rat model of irritable bowel syndrome. Proc Natl Acad Sci. 2011;108(27):11268-11273.
Kerckhove N, Scanzi J, Pereira B, Ardid D, Dapoigny M. Assessment of the effectiveness and safety of ethosuximide in the treatment of abdominal pain related to irritable bowel syndrome-IBSET: protocol of a randomised, parallel, controlled, double-blind and multicentre trial. BMJ Open. 2017;7(7):e015380.
Seyedmirzaee S, Hayatbakhsh MM, Ahmadi B. Serum immune biomarkers in irritable bowel syndrome. Clin Res Hepatol Gastroenterola. 2016;40(5):631-637.
Lee JY, Kim N, Park JH, et al., Expression of Neurotrophic Factors, Tight Junction Proteins, and Cytokines According to the Irritable Bowel Syndrome Subtype and Sex. J Neurogastroenterol Motil. 2020;26(1):106-116.
Rai RR, Nijhawan S. Comparative evaluation of efficacy and safety of drotaverine versus mebeverine in irritable bowel syndrome: A randomized double-blind controlled study. Saudi J Gastroenterol: Official Journal of the Saudi Gastroenterology Association. 2021;27(3):136-143.
Hasan AA, Samir RM, Abu-Zaid SS, Abu Lila AS. Mebeverine hydrochloride loaded chitosan microspheres as potential treatment targeting irritable bowel syndrome: Box-Behnken Design optimization. Int J Pharm Invest. 2020;10(3):326-331.
Karlsson Lind L. Antiepileptic drug utilization: need of sex-specific information and decision support. 2018.
Mearin F, Ciriza C, Mínguez M, et al. Clinical practice guideline: irritable bowel syndrome with constipation and functional constipation in the adult. Rev Esp Enferm Dig. 2016;108(6):332-363.
Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(10):1474-1482.
Bashashati M, Moradi M, Sarosiek I. Interleukin-6 in irritable bowel syndrome: A systematic review and meta-analysis of IL-6 (-G174C) and circulating IL-6 levels. Cytokine. 2017;99:132-138.
Jonefjäll B, Öhman L, Simrén M, Strid H. IBS-like Symptoms in patients with ulcerative colitis in deep remission are associated with increased levels of serum cytokines and poor psychological well-being. Inflamm Bowel Dis. 2016;22(11):2630-2640.
Vara EJ, Brokstad, KA, Hausken, T, Lied, GA, Altered levels of cytokines in patients with irritable bowel syndrome are not correlated with fatigue. Int J Gen Med. 2018;11:285.
Hustoft T N, Hausken T, Ystad S O, et al. Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2017;29(4):e12969.
Bennet SMP, Palsson O, Whitehead WE, et al. Systemic cytokines are elevated in a subset of patients with irritable bowel syndrome but largely unrelated to symptom characteristics. Neurogastroenterol Motil. 2018;30(10):e13378.
Berg LK, Goll R, Fagerli E, et al. Intestinal inflammatory profile shows increase in a diversity of biomarkers in irritable bowel syndrome. Scand J Gastroenterol. 2020;55(5):537-542.
Seyedmirzaee S, Hayatbakhsh MM, Ahmadi B, et al. Serum immune biomarkers in irritable bowel syndrome. Clin Res Hepatolo Gastroenterolo. 2016;40(5):631-637.
Norlin AK, Walter S, Icenhour A, Keita ÅV et al. Fatigue in irritable bowel syndrome is associated with plasma levels of TNF-α and mesocorticolimbic connectivity. Brain Behav Immun. 2021;92:211-222.
Li B, Rui J, Ding X, Yang X. Exploring the multicomponent synergy mechanism of Banxia Xiexin decoction on irritable bowel syndrome by a systems pharmacology strategy. J Ethnopharmacol. 2019;233:158-168.
Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol. 2005;77(5):598-625.
Lau D, Baldus S. Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharmacol Ther. 2006;111(1):16-26.
Pattison D, Davies M. Reactions of myeloperoxidase-derived oxidants with biological substrates: gaining chemical insight into human inflammatory diseases. Curr Med Chem. 2006;13(27):3271-3290.
Hansberry DR, Shah K, Agarwal P, Agarwal N. Fecal myeloperoxidase as a biomarker for inflammatory bowel disease. Cureus. 2017;9(1).
Majeed M, Nagabhushanam K, Arumugam S, Majeed S, Ali F. Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, double-blind, placebo controlled, multi-centre, pilot clinical study. Food Nutr Res. 2018;62.
Zhu H, Xiao X, Chai Y, Li D, Yan X, Tang H. MiRNA-29a modulates visceral hyperalgesia in irritable bowel syndrome by targeting HTR7. Biochem Biophys Res Comm. 2019;511(3):671-678.
Kerckhove N, Scanzi J, Pereira B, Ardid D, Dapoigny M. Assessment of the effectiveness and safety of ethosuximide in the treatment of abdominal pain related to irritable bowel syndrome - IBSET: protocol of a randomised, parallel, controlled, double-blind and multicentre trial. BMJ Open. 2017;7(7):e015380.